ACE-话题@MedSci

#ACE#

496篇内容 | 2889人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1656083, encodeId=c61f16560834b, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, objectType=article, longId=219842, objectId=267d219842d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=267d219842d5, replyNumber=0, likeNumber=88, createdTime=2022-06-09, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=267d219842d5, moduleTitle=Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=267d219842d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656092, encodeId=e9321656092a6, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=MOL THER| 妙！科学家发现咀嚼含有ACE2蛋白的口香糖或减少SARS-CoV-2传播, objectType=article, longId=294400, objectId=c64029440082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c64029440082, replyNumber=0, likeNumber=106, createdTime=2022-07-04, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c64029440082, moduleTitle=MOL THER| 妙！科学家发现咀嚼含有ACE2蛋白的口香糖或减少SARS-CoV-2传播, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c64029440082)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656094, encodeId=535316560944a, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, objectType=article, longId=295066, objectId=890729506606, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=890729506606, replyNumber=0, likeNumber=67, createdTime=2022-09-05, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=890729506606, moduleTitle=Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=890729506606)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656080, encodeId=efc31656080eb, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=ACS APPLIED MATERIALS&INTERFACES：攻克阿尔茨海默症的曙光！纳米酶复合材料或可改善阿尔茨海默症, objectType=article, longId=219062, objectId=d89e21906250, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d89e21906250, replyNumber=0, likeNumber=142, createdTime=2021-12-09, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d89e21906250, moduleTitle=ACS APPLIED MATERIALS&INTERFACES：攻克阿尔茨海默症的曙光！纳米酶复合材料或可改善阿尔茨海默症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d89e21906250)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656096, encodeId=48cd1656096d9, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Nature：新冠溯源新突破，发现可通过ACE2感染人类细胞的蝙蝠冠状病毒, objectType=article, longId=299194, objectId=902d299194f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=902d299194f6, replyNumber=0, likeNumber=75, createdTime=2022-04-09, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=902d299194f6, moduleTitle=Nature：新冠溯源新突破，发现可通过ACE2感染人类细胞的蝙蝠冠状病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=902d299194f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656099, encodeId=3cfe165609930, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=新型取栓技术（SPACEMAN）的技术考虑和应用场景：一项前瞻性研究, objectType=article, longId=300238, objectId=50113002384a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50113002384a, replyNumber=0, likeNumber=98, createdTime=2022-08-21, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50113002384a, moduleTitle=新型取栓技术（SPACEMAN）的技术考虑和应用场景：一项前瞻性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50113002384a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656073, encodeId=1f5316560e324, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药, objectType=article, longId=217612, objectId=ab6b21e61271, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6b21e61271, replyNumber=0, likeNumber=81, createdTime=2022-07-17, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6b21e61271, moduleTitle=Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6b21e61271)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656060, encodeId=89dd165606094, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, objectType=article, longId=212415, objectId=b72721241538, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b72721241538, replyNumber=0, likeNumber=76, createdTime=2021-09-22, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b72721241538, moduleTitle=Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b72721241538)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656081, encodeId=16901656081db, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, objectType=article, longId=219192, objectId=ab6d21919256, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab6d21919256, replyNumber=0, likeNumber=66, createdTime=2022-09-20, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab6d21919256, moduleTitle=Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab6d21919256)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656085, encodeId=fdd4165608507, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析, objectType=article, longId=220980, objectId=a59a2209806a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59a2209806a, replyNumber=0, likeNumber=89, createdTime=2022-09-29, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59a2209806a, moduleTitle=使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a59a2209806a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656059, encodeId=e2011656059d0, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=The Ocular Surface：女性喝酒易患干眼症，男性喝酒可防干眼症？, objectType=article, longId=212221, objectId=6f2121222151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f2121222151, replyNumber=0, likeNumber=74, createdTime=2021-08-22, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f2121222151, moduleTitle=The Ocular Surface：女性喝酒易患干眼症，男性喝酒可防干眼症？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f2121222151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656061, encodeId=b3cd165606125, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！, objectType=article, longId=213452, objectId=4a9121345224, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a9121345224, replyNumber=0, likeNumber=137, createdTime=2022-03-16, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a9121345224, moduleTitle=Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a9121345224)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656075, encodeId=cf2516560e5b8, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, objectType=article, longId=217963, objectId=568c21e96338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=568c21e96338, replyNumber=0, likeNumber=76, createdTime=2022-04-23, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=568c21e96338, moduleTitle=Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=568c21e96338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656068, encodeId=8724165606871, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=数字疗法巨头诞生！心理健康巨头Headspace 和 Ginger 合并市值超30 亿美元, objectType=article, longId=216323, objectId=2b552163233a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b552163233a, replyNumber=0, likeNumber=0, createdTime=2021-12-20, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b552163233a, moduleTitle=数字疗法巨头诞生！心理健康巨头Headspace 和 Ginger 合并市值超30 亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b552163233a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656066, encodeId=940c16560669c, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险, objectType=article, longId=215846, objectId=377e2158469e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=377e2158469e, replyNumber=0, likeNumber=83, createdTime=2022-01-04, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=377e2158469e, moduleTitle=JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=377e2158469e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656050, encodeId=cf381656050da, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素, objectType=article, longId=208174, objectId=8b4b2081e4b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b4b2081e4b2, replyNumber=0, likeNumber=73, createdTime=2021-03-19, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b4b2081e4b2, moduleTitle=Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b4b2081e4b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656084, encodeId=d7f11656084e2, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, objectType=article, longId=219974, objectId=ad462199e46a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad462199e46a, replyNumber=0, likeNumber=68, createdTime=2022-05-01, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad462199e46a, moduleTitle=Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad462199e46a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656045, encodeId=74a916560454d, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒, objectType=article, longId=205740, objectId=214b205e4021, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=214b205e4021, replyNumber=0, likeNumber=123, createdTime=2021-03-19, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=214b205e4021, moduleTitle=ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=214b205e4021)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656049, encodeId=334c1656049ca, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据, objectType=article, longId=207251, objectId=158620e25189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=158620e25189, replyNumber=0, likeNumber=109, createdTime=2021-10-03, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=158620e25189, moduleTitle=Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=158620e25189)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1656043, encodeId=941016560431b, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, objectTitle=NEJM：白介素-1阻滞剂Rilonacept用于复发性心包炎的治疗, objectType=article, longId=205454, objectId=6ca6205454ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ca6205454ce, replyNumber=0, likeNumber=93, createdTime=2021-03-16, rootId=0, userName=shanyongle, userId=635024767990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ca6205454ce, moduleTitle=NEJM：白介素-1阻滞剂Rilonacept用于复发性心包炎的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ca6205454ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ACE

2020-05-29

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Rhizen Pharmaceuticals AG宣布，在一项有关使用其新型PARP抑制剂(RP12146)治疗晚期实体瘤的I/Ib期研究中进行了首例患者给药

2022-06-09

shanyongle (审核中...)

前往app查看评论内容

#ACE#

MOL THER| 妙！科学家发现咀嚼含有ACE2蛋白的口香糖或减少SARS-CoV-2传播

2022-07-04

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Front Oncol：TACE联合AC（阿帕替尼+卡瑞利珠单抗）较AC治疗改善不可切除肝细胞癌（HCC）患者的预后

2022-09-05

shanyongle (审核中...)

前往app查看评论内容

#ACE#

ACS APPLIED MATERIALS&INTERFACES：攻克阿尔茨海默症的曙光！纳米酶复合材料或可改善阿尔茨海默症

2021-12-09

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Nature：新冠溯源新突破，发现可通过ACE2感染人类细胞的蝙蝠冠状病毒

2022-04-09

shanyongle (审核中...)

前往app查看评论内容

#ACE#

新型取栓技术（SPACEMAN）的技术考虑和应用场景：一项前瞻性研究

2022-08-21

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Rhizen Pharmaceuticals AG宣布，RP7214治疗新冠肺炎患者2期研究进行首例患者给药

2022-07-17

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Cancers：中性粒细胞/淋巴细胞比（NLR）是中期肝细胞癌（HCC）患者一线接受TACE治疗的预后指标。

2021-09-22

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Front Oncol：TACE联合索拉非尼或阿帕替尼治疗伴有门脉癌栓（PVTT）的肝细胞癌（HCC）患者的疗效

2022-09-20

shanyongle (审核中...)

前往app查看评论内容

#ACE#

使用TACE联合放疗治疗原发性肝癌合并门静脉癌栓对患者生存情况的影响分析

2022-09-29

shanyongle (审核中...)

前往app查看评论内容

#ACE#

The Ocular Surface：女性喝酒易患干眼症，男性喝酒可防干眼症？

2021-08-22

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Cardiovasc Diabetol：胰岛素治疗显著增加合并ACS的T2D患者的MACE复发风险！

2022-03-16

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Liver Cnacer：真实世界评估仑伐替尼（Lenvatinib）治疗不可切除的肝细胞癌(HCC)的疗效

2022-04-23

shanyongle (审核中...)

前往app查看评论内容

#ACE#

数字疗法巨头诞生！心理健康巨头Headspace 和 Ginger 合并市值超30 亿美元

2021-12-20

shanyongle (审核中...)

前往app查看评论内容

#ACE#

JACC：缓激肽受体B2基因附近的常见变异可增加ACEi相关血管性水肿风险

2022-01-04

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Eur Radiol：在肝细胞癌TACE术中及术后发生严重腹痛的预测因素

2021-03-19

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Hepatology International：索拉非尼- TACE治疗后难治性不可切除肝细胞癌(HCC)续贯使用阿帕替尼的疗效

2022-05-01

shanyongle (审核中...)

前往app查看评论内容

#ACE#

ARTMS和Telix Pharmaceuticals宣布利用从固态靶材通过回旋加速器产出的68Ga，成功生产出PSMA-11试剂盒

2021-03-19

shanyongle (审核中...)

前往app查看评论内容

#ACE#

Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据

2021-10-03

shanyongle (审核中...)

前往app查看评论内容

#ACE#

NEJM：白介素-1阻滞剂Rilonacept用于复发性心包炎的治疗

2021-03-16

科室
- - 订阅+
  - 更多科室
工具
服务